Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesNew therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab
Current Osteoporosis Reports, 09/09/09
Silverman SL – Zoledronic acid significantly reduced the risk of vertebral, nonvertebral, and hip fractures in postmenopausal women. Denosumab is a monoclonal receptor activator of nuclear factor–kB ligand antibody given by subcutaneous injection every 6 months that has been shown to significantly reduce risk of vertebral–, nonvertebral–, and hip fracture in postmenopausal women. Bazedoxifene, an estrogen agonist/antagonist, has significantly reduced the risk of vertebral fracture in postmenopausal women; a post hoc analysis showed reduction in risk of nonvertebral fracture in high–risk women.
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09
Sponsor
Article Search
Sponsor